Chemical Compound with Triazine Group and Production Method
Summary
The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.
What changed
This document is a publication of a patent application (US20260085087A1) by the USPTO, detailing a chemical compound with a triazine group and its production method. The invention focuses on nucleotides and oligonucleotides with modified phosphate groups, aiming to provide compounds with therapeutic potential and an improved production method. Potential applications include cytological studies, pathogen diagnostics, gene therapy, and treatment of bacterial and viral diseases, specifically mentioning COVID-19.
As this is a patent application publication, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, companies in the pharmaceutical and biotechnology sectors may wish to review the application for potential intellectual property insights, competitive intelligence, or future licensing opportunities. The filing date was October 13, 2021, and the publication date is March 26, 2026.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME
Application US20260085087A1 Kind: A1 Mar 26, 2026
Inventors
Maxim Sergeevich KUPRYUSHKIN, Timofei Dmitrievich ZHARKOV, Ilya Sergeevich DOVYDENKO, Oleg Vladimirovich MARKOV
Abstract
A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.
CPC Classifications
C07H 21/00 A61K 31/7125 A61P 35/00
Filing Date
2021-10-13
Application No.
18031420
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.